Transgenic Aloe Plants for Biopharmaceutical Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing therapeutic proteins are expensive, time-consuming, and prone to cross-contamination, with complex extraction and purification processes that are not suitable for underdeveloped countries, and often rely on animal-based systems that introduce health risks.
Innovation Solution
Development of transgenic aloe plants that stably incorporate genes encoding biologically active proteins, allowing for the production of proteins like interferons, immunoglobulins, and growth factors, with the proteins localized in the aloe leaf gel for easy extraction and reduced processing needs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If animal-based protein production methods are used, then production capacity is achieved, but health risks from cross-contamination arise
Solution Approach 1:
The patent uses plants as an intermediary host system for protein production. Instead of directly using animal cells which risk cross-contamination with human pathogens, the invention introduces recombinant DNA into plant cells that will produce the desired human proteins. The plant serves as a safe intermediate production system that eliminates disease transmission risks while still achieving therapeutic protein production.
2Productivity
If complex extraction and purification processes are used, then therapeutic protein production is achieved, but process complexity and cost increase
Solution Approach 1:
The patent targets the extraction of therapeutic proteins specifically from the plant system where they are produced. By localizing protein production in plant tissues and using targeted extraction methods, the invention simplifies the overall process compared to traditional animal-based systems that require extensive purification steps to remove contaminants and achieve therapeutic-grade purity.
3Productivity
If traditional production facilities are built, then production capacity is increased, but construction time and cost increase
Solution Approach 1:
The patent employs a plant-based production system that can be established more quickly and cheaply than traditional animal cell culture facilities. Plants can be grown in various environments including outdoor fields, reducing the need for expensive, highly controlled facility construction. This approach enables faster deployment of production capacity, particularly beneficial for underdeveloped regions.
4Productivity
If animal-based production systems are used, then protein production is achieved, but ease of operation is reduced due to contamination risks
Solution Approach 1:
The patent uses plants as an intermediary host system for protein production. Instead of directly using animal cells which risk cross-contamination, the invention introduces recombinant DNA into plant cells that will produce the desired human proteins. The plant serves as a safe intermediate production system that eliminates disease transmission risks while still achieving therapeutic protein production.
Data Source
AI summary
The present inventions provide transgenic aloe plants and recombinant constructs for transforming aloe plants, aspects of which, may be applied to other monocots. The recombinant constructs may include one or more DNA sequences encoding mammalian proteins and at least one promoter capable of directing the expression of recombinant proteins in an aloe plant. The present inventions also provide methods for constructing and reproducing a transgenic aloe plant. The present inventions include methods for transfection of an aloe plant with several genes of interest simultaneously. The aloe plant production methods of the inventions may provide the potential to inexpensively and more safely mass-produce some biologically active compounds including biopharmaceuticals for disease therapy, diagnosis and prevention, and is more accessible to the less affluent countries. The aloe plant production methods may also produce proteins for cosmetics.